|[August 12, 2014]
Research and Markets: Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/jqtw8n/global_macular)
has announced the addition of the "Global
Macular Edema Market 2014-2018" report to their offering.
The Global Macular Edema market will grow at a CAGR of 9.1% over the
NICE issues and updates technology appraisals and clinical guidelines to
recommend appropriate and effective treatments for different diseases.
It plays a role in increasing drug sales. In January 2013, NICE
recommended Lucentis for the treatment of DME. This recommendation
superseded the November 2011 guidance, which concluded that recommending
Lucentis was not effective utilization of NHS resources. Lucentis has
also been recommended for the treatment of vision impairment as a result
of macular edema associated with RVO
According to the report, the Global Macular Edema market is driven by
several factors, of which the increase in the patient population is one
of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD (News - Alert),
inflammatory conditions such as uveitis, and RVO cause macular edema.
The increase in the incidence and prevalence of ophthalmological
conditions such as AMD and DR is expected to increase the patient
population with macular edema during the forecast period.
Further, the report states that although the Global Macular Edema market
has several drivers, the growth of the market is curtailed by some
serious challenges. One of the main challenges is increased use of
off-label drugs. Use of off-label drugs increases the market competition
for approved branded drugs. Some of the off-label drugs for the
treatment of macular edema are bevacizumab, topical NSAIDs, and drugs
such as acetazolamide.
The report also includes a discussion of the other vendors operating in
this market. The study was conducted using an objective combination of
primary and secondary information including inputs from key participants
in the industry. The report contains a comprehensive market and vendor
landscape in addition to a SWOT analysis of the key vendors.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals Inc.
Other Prominent Vendors
Alimera Sciences Inc.
Ampio Pharmaceuticals Inc.
iCo Therapeutics Inc.
Santen Pharmaceutical Co. Ltd.
For more information visit http://www.researchandmarkets.com/research/jqtw8n/global_macular
[ InfoTech Spotlight's Homepage ]